Optimizing glycoprotein IIb/IIIa inhibition: Lessons from recent randomized controlled trials

Internal Medicine Journal

Volumn 32, Issue 7, 2002, Pages 338-345

  Chew, D P ^a   Bhatt, D L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute coronary syndromes; Coronary intervention; Glycoprotein IIb IIIa inhibition; Platelets

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ANGINA PECTORIS; BINDING AFFINITY; BLOOD CLOT LYSIS; CELL INTERACTION; CLINICAL TRIAL; CORONARY STENT; DOSE RESPONSE; DRUG BINDING SITE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; REVIEW; SIDE EFFECT; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

ACUTE DISEASE; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RISK FACTORS; SYNDROME; TIME FACTORS; TREATMENT OUTCOME; TYROSINE;

EID: 0036380962     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-5994.2002.00226.x     Document Type: Review

References (42)

1. Chew D, Moliterno D. Critical appraisal of glycoprotein IIb/IIIa inhibition. J Am Coll Cardiol 2000; 36: 2020-35.
2. Chew D, Bhatt D, Sapp S, Topol E. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a pooled analysis of the large scale oral glycoprotein IIb/IIIa trials. Circulation 2001; 103: 201-6.
3. Kong DF, Califf RM, Miller DP et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829-35.
4. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000; 284: 1549-58.
5. The EPIC Investigation Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956-61.
6. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336: 1689-96.
7. Lincoff AM, Califf RM, Moliterno DJ et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999; 341: 319-27.
8. Lincoff AM, Califf RM, Anderson KM et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol 1997; 30: 149-56.
9. Brener SJ, Barr LA, Burchenal JE et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98: 734-41.
10. Schomig A, Kastrati A, Dirschinger J et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 2000; 343: 385-91.
11. IMPACT-II Investigators Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349: 1422-8.
12. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa: blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and RE stenosis. Circulation 1997; 96: 1445-53.
13. Topol E, Moliterno DJ, Herrmann HC et al. Comparison of two platelet glycoprotein Iib/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-94.
14. The PARAGON Investigators International, randomized controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor) heparin or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 1998; 97: 2386-95.
15. The PURSUIT Trial Investigators Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339: 436-43.
16. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998; 338: 1488-97.
17. Platelet Receptor Inhibition in Iscemic Syndrome Management (PRISM) Study Investigators A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998; 338: 1498-505.
18. Cannon C, Weintraub W, Demopoulos L et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein Iib/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-87.
19. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 1995; 74: 302-8.
20. Coller BS. Current concepts of thrombosis. J Invasive Cardiol 1994; 6: 277-84.
21. Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation 1989; 80: 1766-74.
22. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-31.
23. Peter K, Schwarz M, Ylanne J et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998; 92: 3240-9.
24. Peter K, Straub A, Kohler B et al. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Am J Cardiol 1999; 84: 519-24.
25. Gawaz M, Ruf A, Neumann FJ et al. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost 1998; 80: 994-1001.
26. Cierniewski CS, Byzova T, Papierak M et al. Peptide ligands can bind to distinct sites in integrin alphaIIbbeta3 and elicit different functional responses. J Biol Chem 1999; 274: 16 923-32.
27. Du XP, Plow EF, Frelinger AL III, O'Toole TE, Loftus JC, Ginsberg MH. Ligands'activate' integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell 1991; 65: 409-16.
28. Coller BS. Potential non-glycoprotein IIb/IIIa effects of abciximab. Am Heart J 1999; 138: S1-5.
29. Neumann FJ, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999; 34: 1420-6.
30. Bhatt D, Chew D, Simmons M et al. An elevated white blood cell count is an independent predictor of mortality in patients with acute coronary syndromes. Circulation 2000; 102: II-776.
31. Lagerqvist B, Siegabn A, Diderholm E et al. Raised mortality at inflammatory activity or myocardial damage in unstable CAD is reduced by an invasive strategy. Circulation 2000; 102: II-390.
32. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998; 97: 211-18.
33. Lincoff A, Kereiake D, Mascelli M et al. Abciximab suppresses the rise in plasma levels of inflammatory markers following PTCA. Circulation 2000; 102: II-330.
34. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 antiplatelet therapy in unstable angina refractory to standard treatment trial. J Am Coll Cardiol 2000; 35: 1535-42.
35. 2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997; 96: 1488-94.
36. Kleiman NS, Lincoff AM, Flaker GC et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. Circulation 2000; 101: 751-7.
37. Steinhubl S, Talley D, Kereiakes D et al. A prospective multicentre study to determine the optimal level of platelet inhibition with GP IIb/IIIa inhibitors in patients undergoing coronary intervention-the GOLD study. J Am Coll Cardiol 2000; 35: 44A.
38. Aguirre F, Lam W, Gill J et al. Comparison of platelet inhibition achieved with abciximab vs eptifibatide during percutaneous coronary intervention: influence of platelet inhibition on clinical outcomes. Circulation 2000; SII: 18.
39. Kereiakes DJ, Broderick TM, Roth EM et al. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 1999; 84: 391-5.
40. Montalescot G, Barragan P, Wittenberg O et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-903.
41. Hamm CW, Heeschen C, Goldmann B et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999; 340: 1623-9.
42. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999; 354: 1757-62.